カテゴリ： GlobalData, アメリカ, 企業調査

AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：AMAG Pharmaceuticals Inc (AMAG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012243
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth in women, Feraheme (ferumoxytol) for iron deficiency anemia in adult patients with chronic kidney disease and MuGard Oral Mucoadhesive for the management of oral mucositis and all types of oral wounds including aphthous ulcers/canker sores and traumatic ulcers. AMAG also provides services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units. The company offers these products through direct sales and a network of distributors. It has presence in the US, Switzerland and the UK. AMAG is headquartered in Waltham, Massachusetts, the US.

AMAG Pharmaceuticals Inc (AMAG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
Private Equity 15
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Partnerships 17
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
Licensing Agreements 18
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
Equity Offering 24
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
Debt Offering 29
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Asset Transactions 34
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
Acquisition 35
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc – Key Competitors 40
AMAG Pharmaceuticals Inc – Key Employees 41
AMAG Pharmaceuticals Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Nov 02, 2017: AMAG Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Highlights 45
Aug 03, 2017: AMAG Pharmaceuticals Announces Second Quarter 2017 Financial Results and Provides Corporate Update 48
May 02, 2017: AMAG Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update 52
Feb 14, 2017: AMAG Reports Fourth Quarter and Full Year 2016 Financial Results 54
Jan 09, 2017: AMAG Pharmaceuticals Provides Financial and Business Update 57
Nov 03, 2016: AMAG Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 59
Aug 09, 2016: AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 61
May 03, 2016: AMAG Pharmaceuticals Reports First Quarter 2016 Financial Results 64
Feb 17, 2016: AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results 66
Corporate Communications 68
Sep 29, 2017: AMAG Pharmaceuticals Appoints Tracy Palmer Berns as Chief Compliance Officer 68
Sep 07, 2017: AMAG Pharmaceuticals Appoints Laura Williams, M.D. as Senior Vice President of Clinical Development 69
Apr 25, 2017: AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmacovigilance 70
Mar 06, 2017: AMAG Announces Management Changes and New Commercial Appointments 71
Dec 21, 2016: AMAG Pharmaceuticals Announces Appointment of Brian Kelley to Board of Directors 72
Apr 11, 2016: AMAG Pharmaceuticals Appoints Edward Myles as Chief Financial Officer 73
Jan 04, 2016: AMAG Pharmaceuticals Appoints Nicholas Grund as Chief Commercial Officer 74
Government and Public Interest 75
Dec 15, 2016: AMAG Pharmaceuticals Doubles Support of Prematurity Prevention Research 75
Product News 76
04/04/2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 76
02/02/2017: AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration 77
Product Approvals 78
Jun 26, 2017: AMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector 78
Apr 17, 2017: AMAG Submits Supplemental New Drug Application to FDA for Makena (Hydroxyprogesterone Caproate Injection) Auto-Injector for Subcutaneous Use 79
Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection) 81
Clinical Trials 82
Oct 12, 2016: AMAG Pharmaceuticals Announces Achievement of Key Milestone in Next Generation Development Program for Makena 82
Other Significant Developments 83
Nov 08, 2017: AMAG Announces Autologous Cord Blood Cells Improve Motor Function in Some Children with Cerebral Palsy 83
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
AMAG Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
AMAG Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
AMAG Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
AMAG Pharma Enters into Option Agreement to Acquire Rights of Orphan Drug Candidate from Velo Bio 14
GTCR Invests In Cord Blood Registry 15
MSMB Capital Management To Acquire AMAG Pharma 16
Cord Blood Registry Enters into Research Agreement with Cellular Dynamics 17
AMAG Pharma and Endoceutics Pharma Enter into Licensing Agreement 18
AMAG Pharma Enters into Licensing Agreement with Palatin Tech 20
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 22
AMAG Pharma Raises USD230.9 Million in Public Offering of Shares 24
AMAG Pharma Raises USD201 Million in Public Offering of Shares 26
Amag Pharma Files Registration Statement For Public Offering Of Securities For Up To US$250 Million 28
AMAG Pharma Prices Public Offering of 3.25% Notes Due 2022 for USD300 Million 29
AMAG Pharma Raises USD500 Million in Private Placement of 7.878% Notes Due 2023 31
Amag Pharma Completes Public Offering Of Notes Due 2019 For US$200 Million 32
Amag Pharma Plans For Sale Of Drug Manufacturing Facility 34
AMAG Pharma Acquires Cord Blood Registry for USD700 Million 35
AMAG Pharma Acquires Lumara Health 37
AMAG Pharma Plans For Sale Of The Company 39
AMAG Pharmaceuticals Inc, Key Competitors 40
AMAG Pharmaceuticals Inc, Key Employees 41
AMAG Pharmaceuticals Inc, Other Locations 43
AMAG Pharmaceuticals Inc, Subsidiaries 43

★海外企業調査レポート[AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Bloomsbury Publishing Plc (BMY)：企業の財務・戦略的SWOT分析
    Bloomsbury Publishing Plc (BMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Symrise AG (SY1)：製薬・医療：M&Aディール及び事業提携情報
    Summary Symrise AG (Symrise) offers flavors and fragrances. The company develops, produces and sells flavorings, fragrances, cosmetic active ingredients and raw materials, and functional ingredients and solutions for the cosmetics industry. It also provides biofunctional and bioactive ingredients an …
  • J.W. Ostendorf Gmbh & Co Kg
    J.W. Ostendorf Gmbh & Co Kg - Strategy, SWOT and Corporate Finance Report Summary J.W. Ostendorf Gmbh & Co Kg - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nine Dragons Paper (Holdings) Ltd：企業の戦略・SWOT・財務情報
    Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Dragons Paper (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Brasfield & Gorrie LLC：企業の戦略・SWOT・財務情報
    Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report Summary Brasfield & Gorrie LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Driver Group Plc (DRV)：企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Companhia Paranaense de Energia SA (CPLE6)：電力：M&Aディール及び事業提携情報
    Summary Companhia Paranaense de Energia SA (Copel) is an integrated electric utility. It generates, transmits, distributes and sells electricity. The company produces electricity from hydro, wind, and thermal sources. Copel explores oil and natural gas; and distributes natural gas. It holds rights t …
  • Central Securities Corp (CET)：企業の財務・戦略的SWOT分析
    Summary Central Securities Corp (Central Securities) is a financial service provider that provides investment services. The company offers investment management services and stock investment related services. It invests on convertible preferred stocks, bonds, preferred stocks, convertible bonds, war …
  • Revalesio Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Revalesio Corp (Revalesio) is a developer of novel therapeutics for the treatment of inflammatory diseases. The company conducts research and development activities to develop therapeutics in the areas of respiratory, neuroscience and cardiovascular. Its product pipeline includes drugs targe …
  • Medytox Inc (086900)：企業の財務・戦略的SWOT分析
    Summary Medytox Inc (Medytox) develops, manufactures and markets biopharmaceutical products. Its products include botulinum toxin type A product, hyaluronic acid filler, medical devices, prescription cream, toxin detection kits and antitoxin therapeutics for treating skin disorders. The company is a …
  • Perma-Fix Environmental Services Inc (PESI)：企業の財務・戦略的SWOT分析
    Perma-Fix Environmental Services Inc (PESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Brazil Fast Food Corp.：企業の戦略・SWOT・財務分析
    Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report Summary Brazil Fast Food Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ardian Holding SAS：企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Sunningdale Tech Ltd (BHQ)：企業の財務・戦略的SWOT分析
    Summary Sunningdale Tech Ltd (Sunningdale) is a chemical company that manufactures and markets tooling and plastic injection moulding components. The company's plastic solutions include product and mould designs, injection moulding, mould fabrication, complementary finishings, and precision assembly …
  • Claris Lifesciences Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Claris Lifesciences Ltd (Claris) is a manufacturer of generic drugs and pharmaceutical products. The company provides generic drugs that are directly injected into the human body, which is mainly used in the treatment of critical illnesses. It provides products are offered through various de …
  • Pear Therapeutics Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Hurtigruten AS：企業の戦略・SWOT・財務情報
    Hurtigruten AS - Strategy, SWOT and Corporate Finance Report Summary Hurtigruten AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Vortex Energy Holding AG：電力：M&Aディール及び事業提携情報
    Summary Vortex Energy Holding AG (Vortex Energy) is a provider of renewable energy services. The company's services include development, consulting, financing, planning, implementation, construction, technical management, technical inspection, commercial management, and energy trading services. It a …
  • United Food Holdings Limited
    United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • API Group plc：企業の戦略・SWOT・財務情報
    API Group plc - Strategy, SWOT and Corporate Finance Report Summary API Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆